BCAB
BioAtla, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+31.44%Sep 29, 2026, 21:29 UTC
Eric Sievers resigned as Chief Medical Officer of BioAtla, Inc., effective September 25, 2026, with a one-time severance payment of $159,000 contingent on the company meeting certain capital raising milestones by December 31, 2026.
Source:Sep 29, 2026, 21:29 UTC
BioAtla, Inc. reinstated a retention bonus program for CEO Jay M. Short, effective September 24, 2026, with a target retention bonus of $440,892 and a target performance bonus of $220,000.
Sep 29, 2026, 21:29 UTC
BioAtla, Inc. approved retention bonus and performance bonus arrangements for CFO Christian Vasquez, effective September 24, 2026, including a target retention bonus of $148,888 and a target performance bonus of $75,000.
Aug 18, 2026, 16:15 UTC
Biokin Pharma announced that its bispecific ADC iza-bren met the primary endpoint in the Panku-Lung01 phase 3 lung cancer trial, showing significant progression-free survival benefit.
Source: